Atossa Therapeutics Q3 net loss widens as operating costs rise

Atossa Therapeutics

12/11/2025 13:24

Overview

Atossa Therapeutics Q3 net loss widens to $8.7 mln, operating expenses rise to $9.3 mln

Company advances (Z)-endoxifen program with regulatory strategies and clinical trials

Appointed key leadership roles to drive (Z)-endoxifen development and commercialization and streamline development programs

Outlook

Atossa targets IND submission for (Z)-endoxifen in Q4 2025

Company plans to update shareholders on FDA meeting outcome by year-end 2025

Atossa focuses on NDA-enabling activities for (Z)-endoxifen in 2026

Result Drivers

R&D EXPENSES - Increased R&D expenses due to higher spending on (Z)-endoxifen trials and drug development costs

REGULATORY STRATEGY - Co requested a Type C meeting with FDA to accelerate (Z)-endoxifen development for breast cancer risk reduction

TRIAL STREAMLINING - Streamlined EVANGELINE breast cancer trial to focus on NDA-enabling activities and reduce costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.07
Q3 Net Income
-$8.69 mln
Q3 Operating Expenses
$9.25 mln
Q3 Operating Income
-$9.25 mln
Q3 Pretax Profit
-$8.69 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Atossa Therapeutics Inc is $5.50, about 85% above its November 11 closing price of $0.83

Press Release: ID:nPnBF91Za

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)